Further, ACVR2B/Fc treatment preserved cardiac function in tumour hosts despite no effects in whole‐heart size, thereby demonstrating that targeting ACVR2B signalling may be a viable option in combating multi‐organ dysfunction in advanced metastatic CRC. This evidence concerns the gene ACVR2B and neoplasm.